Treatment of Intermittent Claudication with Mesoglycan – A Placebo-controlled, Double-blind Study

Summary

Objective: To assess the effect of treatment with mesoglycan, a sulphated polysaccharide compound, on the walking capacity of patients with stage II peripheral arterial disease. Methods: Non-diabetic out-patients with intermittent claudication, duplex ultrasound evidence of peripheral atherosclerosis, ankle/arm index <0.80, systolic ankle pressure >50 mmHg, and absolute walking distance (AWD) between 100 and 300 m (standardised treadmill test) were eligible. After a 5-week run-in on single-blind placebo, patients were randomised to double-blind treatment with mesoglycan, 30 mg/day intramuscularly for 3 weeks followed by 100 mg/day orally for 20 weeks, or matching placebo. All patients received low-dose aspirin and lifestyle instructions. Clinical response was defined as an AWD increase at Week 23 >50% over baseline. Health-related quality of life and ischaemic events were assessed as secondary efficacy variables. Results: 242 patients were randomised and 237 were assessed for clinical response. Patients achieving clinical response were 59/118 with mesoglycan (50.0%) and 31/119 with placebo (26.1%; p <0.001). Geometric mean AWD increased from 192 to 298 m with mesoglycan, and from 192 to 238 m with placebo (p <0.001). Pain-free walking distance showed a non-significant increase with mesoglycan (p = 0.057). Changes in quality of life scores were in favour of mesoglycan. The rate of ischaemic events was 1/120 on mesoglycan and 6/122 on placebo (p = 0.053). The rate of non-ischaemic adverse events leading to treatment discontinuation was 7/120 and 4/122, respectively. Conclusion: Treatment with mesoglycan improves the walking capacity of patients with intermittent claudication, and might confer additional antithrombotic protection over that of aspirin.

Keywords

Peripheral arterial disease - intermittent claudication - treadmill test - mesoglycan - randomised clinical trial

• References

• 1 TransAtlantic Inter-Society Consensus (TASC).. Management of peripheral arterial disease (PAD). Eur J Vasc Endovasc Surg 2000; 19 (suppl A): S1-250.
• 2 Jackson MR, Clagett GP. Antithrombotic Therapy in Peripheral Arterial Occlusive Disease. Chest 2001; 119 Suppl 283S-299S.
• 3 Ofosu FA, Modi GJ, Smith LM, Cerksus AL, Hirsh J, Blajchman MA. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 742-7.
• 4 Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-14.
• 5 Bianchini P, Osima B, Parma B, Nader HB, Dietrich CP. Lack of correlation between in vitro and in vivo antithrombotic activity of heparin fractions and related compounds. Heparan sulfate as an antithrombotic agent in vivo. Thromb Res 1985; 40: 597-607.
• 6 Maggi A, Abbadini N, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis 1987; 17: 329-35.
• 7 Forconi S, Battistini N, Guerrini M, Passero SG. for the SIAM group.. A randomized, ASA-controlled trial of mesoglycan in secondary prevention after cerebral ischemic events. Cerebrovasc Dis 1995; 5: 334-41.
• 8 Agnelli G, Cosmi B, Di Filippo P, Ranucci V, Veschi F, Longetti M, Renga C, Barzi F, Gianese F, Lupattelli L, Rinonapoli E, Nenci GG. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992; 67: 203-8.
• 9 Di Carlo V, Agnelli G, Prandoni P, Coccheri S, Gensini GF, Gianese F, Mannucci PM. for the DOS Study Group.. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. Thromb Haemost 1999; 82: 30-4.
• 10 Tanganelli P, Bianciardi G, Carducci A, Palummo N, Simoes C, Tarabochia B, Weber G, Verzuri MS, Auteri A. Updating on in-vivo and in-vitro effects of heparin and other glycosaminoglycans (mesoglycan) on arterial endothelium: a morphometrical study. Int J Tissue React 1992; 14: 149-53.
• 11 Laurora G, Cesarone MR, De Sanctis MT, Incandela L, Belcaro G. Delayed arteriosclerosis progression in high risk subjects treated with mesoglycan. Evaluation of intima-media thickness. J Cardiovasc Surg 1993; 34: 313-8.
• 12 Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 1989; 556: 245-54.
• 13 Zanolo G, Giachetti C, Mascellani G, Magliocca R, Ferrari G. Pharmacokinetic aspects of tritium-labeled glycosaminoglycans (mesoglycan). Their absorption in rat and monkey and tissue distribution in rat. Boll Chim Farm 1984; 123: 223-35.
• 14 Dawes J, Hodson BA, Pepper DS. The absorption, clearance and metabolic fate of dermatan sulfate administered to man. Studies using a radioiodinated derivative. Thromb Haemost 1989; 62: 94-9.
• 15 Auteri A, Celasco G, Gasparro MG, Verzuri MS, Artale F, Bandiera G, Bianco E, Campitello F, Colella E, Ferrozzi G, Gagliano A, Locati P, Malacarne P, Zanca M. I glicosaminoglicani nella terapia delle arteriopatie obliteranti periferiche. Studio multicentrico. Giorn It Angiol 1991; 11: 24-30.
• 16 De Donato G, De Nicola P, Meucci E. Valutazione strumentale degli effetti del mesoglicano in pazienti arteriopatici (Stadio II di Fontaine) in uno studio in doppio cieco verso placebo. Farmaci e Terapia 1991; 8: 84-8.
• 17 Raso AM, Maggio D, Trogolo M, Rispoli P, Sandrone N, Pezzuto D, Bellan A, Melloni CD. Efficacia del trattamento con mesoglicano in pazienti con ischemia relativa degli arti inferiori. Minerva Cardioangiol 1997; 45: 383-92.
• 18 European Agency for the Evaluation of Medicinal Products.. Note for guidance on the clinical investigation of medicinal products in the treatment of chronic peripheral arterial occlusive disease. Document CPMP/ EWP/233/95.
• 19 Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston: The Health Institute; 1993
• 20 Apolone G, Mosconi P, Ware JE. Questionario sullo stato di salute SF-36. Milano: Guerini e Associati; 1997
• 21 European Agency for the Evaluation of Medicinal Products.. Note for guidance on Good Clinical Practice. Document CPMP/ICH/135/95.
• 22 Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978; 62: 1037-40.
• 23 Lee AJ, Fowkes FG, Rattray A, Rumley A, Lowe GD. Haemostatic and rheological factors in intermittent claudication: the influence of smoking and extent of arterial disease. Br J Haematol 1996; 92: 226-30.
• 24 Ofosu FA. Pharmacological actions of sulodexide. Semin Thromb Hemost 1998; 24: 127-38.
• 25 Hiebert LM, Wice SM, Jaques LB. Antithrombotic activity of oral unfractionated heparin. J Cardiovasc Pharmacol 1996; 28: 26-9.
• 26 Costantini V, Deveglia R, Stabile A, Nenci GG. Absorption and antithrombotic activity of unfractionated heparin after intraduodenal administration in rats. Blood Coagul Fibrinolysis 2000; 11: 7-13.
• 27 Antonicelli R, Sardina M, Scotti A, Bonizzoni E, Paciaroni E. on behalf of the Italian CAP Study Group.. Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication. Am J Med 1999; 107: 234-9.
• 28 Girolami B, Bernardi E, Prins MH, ten Cate JW, Prandoni P, Hettiarachchi R, Marras E, Stefani PM, Girolami A, Buller HR. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb Haemost 1999; 81: 715-22.
• 29 Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, Forbes WP, Strandness DE. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-30.
• 30 Girolami B, Bernardi E, Prins MH, ten Cate JW, Hettiarachchi R, Prandoni P, Girolami A, Buller HR. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline or nafronyl. A meta-analysis. Arch Intern Med 1999; 159: 337-45.
• 31 Lièvre M, Morand S, Besse B, Fiessinger JN, Boissel JP. on behalf of the BERCI Research Group.. Oral beraprost sodium, a prostaglandin I₂ analogue, for intermittent claudication. A double-blind, randomized, multi-center controlled trial. Circulation 2000; 102: 426-31.